PMID- 35083518
OWN - NLM
STAT- MEDLINE
DCOM- 20220624
LR  - 20220803
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 269
IP  - 7
DP  - 2022 Jul
TI  - Long-term effects of pallidal deep brain stimulation in tardive dystonia: a 
      follow-up of 5-14 years.
PG  - 3563-3568
LID - 10.1007/s00415-022-10965-8 [doi]
AB  - INTRODUCTION: Pallidal DBS is an established treatment for severe isolated 
      dystonia. However, its use in disabling and treatment-refractory tardive 
      syndromes (TS) including tardive dyskinesia and tardive dystonia (TD) is less 
      well investigated and long-term data remain sparse. This observational study 
      evaluates long-term effects of deep brain stimulation (DBS) of the globus 
      pallidus internus (GPi) in patients with medically refractory TS. METHODS: We 
      retrospectively analyzed a cohort of seven TD patients with bilateral GPi-DBS. 
      Involuntary movements, dystonia and disability were rated at long-term follow-up 
      (LT-FU) after a mean of 122 +/- 33.2 SD months (range 63-171 months) and compared 
      to baseline (BL), short-term (ST-FU; mean 6 +/- 2.0 SD months) and 4-year follow-up 
      (4y-FU; mean 45 +/- 12.3 SD months) using the Abnormal Involuntary Movement Scale 
      (AIMS) and the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS), respectively. 
      Quality of life and mood were evaluated using the SF36 and Beck Depression Index 
      (BDI) questionnaires, respectively. RESULTS: At LT-FU patients had improved by 
      73% +/- 14.2 SD in involuntary movements and 90% +/- 1.0 SD in dystonia. Mood had 
      improved significantly whereas quality of life remained unchanged compared to 
      baseline. No serious long-lasting stimulation-related adverse events (AEs) were 
      observed. Three patients of this cohort presented without active stimulation and 
      ongoing symptom relief at long-term follow-up after 3-10 years of continuous DBS. 
      CONCLUSION: Pallidal DBS is a safe and effective long-term TD treatment. Even 
      more interesting, three of our patients could stop stimulation after several 
      years of DBS without serious relapse. Larger studies need to explore the 
      phenomenon of ongoing symptom relief after DBS cessation.
CI  - (c) 2022. The Author(s).
FAU - Krause, Patricia
AU  - Krause P
AUID- ORCID: 0000-0001-9063-0556
AD  - Movement Disorder and Neuromodulation Unit, Department of Neurology, Charite, 
      University Medicine Berlin, Campus Mitte, Chariteplatz 1, 10117, Berlin, Germany.
FAU - Kroneberg, Daniel
AU  - Kroneberg D
AD  - Movement Disorder and Neuromodulation Unit, Department of Neurology, Charite, 
      University Medicine Berlin, Campus Mitte, Chariteplatz 1, 10117, Berlin, Germany.
FAU - Gruber, Doreen
AU  - Gruber D
AD  - Department of Neurology and Stereotactic Surgery, University Medicine of 
      Magdeburg, Magdeburg, Germany.
FAU - Koch, Kristin
AU  - Koch K
AD  - Department of Psychiatry and Psychotherapy, Charite, University Medicine Berlin, 
      Campus Mitte, Berlin, Germany.
FAU - Schneider, Gerd-Helge
AU  - Schneider GH
AD  - Department of Neurosurgery, Charite, University Medicine Berlin, University 
      Medicine Berlin, Campus Mitte, Berlin, Germany.
FAU - Kuhn, Andrea A
AU  - Kuhn AA
AD  - Movement Disorder and Neuromodulation Unit, Department of Neurology, Charite, 
      University Medicine Berlin, Campus Mitte, Chariteplatz 1, 10117, Berlin, Germany. 
      andrea.kuehn@charite.de.
LA  - eng
GR  - SFB 295/Deutsche Forschungsgemeinschaft/
GR  - Lydia Rabinowitsch grant/Charite - Universitatsmedizin Berlin/
GR  - BIH/Charite - Universitatsmedizin Berlin/
PT  - Journal Article
PT  - Observational Study
DEP - 20220127
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
SB  - IM
MH  - *Deep Brain Stimulation
MH  - *Dystonia/therapy
MH  - *Dystonic Disorders/therapy
MH  - Follow-Up Studies
MH  - Globus Pallidus/physiology
MH  - Humans
MH  - Quality of Life
MH  - Retrospective Studies
MH  - *Tardive Dyskinesia/therapy
MH  - Treatment Outcome
PMC - PMC9217904
OTO - NOTNLM
OT  - DBS and quality of life
OT  - Dystonia
OT  - Long-term effects
OT  - Pallidal DBS
OT  - Tardive
COIS- AAK received speaker s honoraria and consultancies from Medtronic and Boston 
      Scientific. P.K. received speaker s honoraria from Medtronic. D.K. is a 
      participant in the BIH-Charite Clinician Scientist Program funded by the 
      Charite-Universitatsmedizin Berlin and the Berlin Institute of Health. D.G. has 
      received honoraria for speaking from Medtronic, outside the submitted work. K.K.: 
      none G.H.S. received speaker's honoraria from Medtronic, Boston Scientific, and 
      Abbott.
EDAT- 2022/01/28 06:00
MHDA- 2022/06/25 06:00
PMCR- 2022/01/27
CRDT- 2022/01/27 05:51
PHST- 2021/10/04 00:00 [received]
PHST- 2022/01/06 00:00 [accepted]
PHST- 2022/01/05 00:00 [revised]
PHST- 2022/01/28 06:00 [pubmed]
PHST- 2022/06/25 06:00 [medline]
PHST- 2022/01/27 05:51 [entrez]
PHST- 2022/01/27 00:00 [pmc-release]
AID - 10.1007/s00415-022-10965-8 [pii]
AID - 10965 [pii]
AID - 10.1007/s00415-022-10965-8 [doi]
PST - ppublish
SO  - J Neurol. 2022 Jul;269(7):3563-3568. doi: 10.1007/s00415-022-10965-8. Epub 2022 
      Jan 27.